
Celadon
CEL.LCeladon Pharmaceuticals Plc Price (CEL.L)
Stock Price
Market Cap
Fetching Data...
Enterprise Value
Fetching Data...
Volume
Fetching Data...
Shares Outstanding
61,893,906
(8.0266)%Income Statement Summary
Revenue | |
Cost of Revenue | |
Gross Profit | |
Operating Expenses | |
Operating Income | |
Other Expenses | |
Net Income |


Income Statement
Celadon Pharmaceuticals PlcCurrency: GBp
YEAR | 2019 | 2020 | 2021 | 2022 | 2023 | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||||||||
Revenue |
0.00
+0% |
0.00
+0% |
2,000.00
+0% |
24,000.00
+1,100% |
75,000.00
+213% |
||||||||||||||
Cost of Revenue | |||||||||||||||||||
Cost of Revenue | 0.00 | 0.00 | 12,000.00 | 90,000.00 | 0.00 | ||||||||||||||
Gross Profit | |||||||||||||||||||
Gross Profit |
0.00
+0% |
0.00
+0% |
-10,000.00
+0% |
-66,000.00
+560% |
75,000.00
-214% |
||||||||||||||
Gross Profit Ratio | (0.00%) | (0.00%) | (-5.00%) | (-2.75%) | (1.00%) | ||||||||||||||
Operating Expenses | |||||||||||||||||||
Research and Development | 0.00 | 217,106.00 | 0.00 | 0.00 | 0.00 | ||||||||||||||
General and Administrative | 47,452.00 | 255,843.00 | 0.00 | 0.00 | 0.00 | ||||||||||||||
Selling, General & Admin... | 47,452.00 | 255,843.00 | 502,187.00 | 12,156,864.00 | 5,757,000.00 | ||||||||||||||
Selling & Marketing Exp... | 119,090.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||||||
Depreciation and Amortiz... | 47,452.00 | 60,398.00 | 319,000.00 | 466,000.00 | 534,000.00 | ||||||||||||||
Other Expenses | 0.00 | 247,698.00 | 2,703,000.00 | 12,851,000.00 | 0.00 | ||||||||||||||
Total Operating Expenses | 47,451.00 | 720,647.00 | 2,703,000.00 | 12,851,000.00 | 5,757,000.00 | ||||||||||||||
Cost and Exponses | 47,451.00 | 720,647.00 | 2,715,000.00 | 12,941,000.00 | 6,381,000.00 | ||||||||||||||
Operating Income | |||||||||||||||||||
Operating Income |
-47,452.00
+0% |
-720,647.00
+1,419% |
-2,713,000.00
+276% |
-5,381,000.00
+98% |
-5,931,000.00
+10% |
||||||||||||||
Operating Income Ratio | (0.00%) | (0.00%) | (-1,356.50%) | (-224.21%) | (-79.08%) | ||||||||||||||
Other Income and Exp... | |||||||||||||||||||
Interest Income | 14,562.00 | 6.00 | 1,511.25 | 12,000.00 | 32,000.00 | ||||||||||||||
Interest Expenses | 0.00 | 339,152.00 | 646,000.00 | 4,040,000.00 | 598,000.00 | ||||||||||||||
Total Other Income/Exp... | -143,868.00 | -339,146.00 | -2,083,000.00 | -12,737,000.00 | -1,592,000.00 | ||||||||||||||
EBITDA | |||||||||||||||||||
EBITDA | -191,320.00 | -660,249.00 | -2,394,000.00 | -13,612,000.00 | -6,391,000.00 | ||||||||||||||
EBITDA ratio | (0.00%) | (0.00%) | (-1,197.00%) | (-518.29%) | (-85.21%) | ||||||||||||||
Income Before Tax | |||||||||||||||||||
Income Before Tax | -151,697.00 | -1,059,793.00 | -4,796,000.00 | -18,118,000.00 | -7,523,000.00 | ||||||||||||||
Income Before Tax Ratio | (0.00%) | (0.00%) | (-2,398.00%) | (-754.92%) | (-100.31%) | ||||||||||||||
Income Tax Expense | |||||||||||||||||||
Income Tax Expense | -47,452.00 | 339,152.00 | -13,000.00 | -707,000.00 | -261,000.00 | ||||||||||||||
Net Income | |||||||||||||||||||
Net Income | -151,697.00
+0% |
-1,398,945.00
+822% |
-4,783,000.00
+242% |
-17,411,000.00
+264% |
-7,140,000.00
-59% |
||||||||||||||
Net Income Ratio | (0.00%) | (0.00%) | (-2,391.50%) | (-725.46%) | (-95.20%) | ||||||||||||||
Earning Per Share | |||||||||||||||||||
Basic EPS | -0.03 | -0.23 | -0.64 | -0.30 | -0.12 | ||||||||||||||
Diluted EPS | -0.03 | -0.23 | -0.64 | -0.30 | -0.12 | ||||||||||||||
Share Outstanding | |||||||||||||||||||
Basic Share Outstanding | 5,313,781.00 | 6,130,000.00 | 7,501,862.00 | 57,295,086.00 | 61,894,276.00 | ||||||||||||||
Diluted Share Outstanding | 5,313,781.00 | 6,130,000.00 | 7,501,862.00 | 57,295,086.00 | 61,893,906.00 |